omniture
logo
Search
沈阳三生制药有限责任公司 S BIO.PHARM.GROUP I
Media Room

Latest News

rss

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2023-08-25 10:06 4537
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HONG KONG, March 22, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK...

2023-03-22 11:15 3125
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company com...

2022-01-29 11:37 6792

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2021-08-26 22:09 5664

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2021-03-31 09:11 3143
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- 3SBio Inc. ("3SBio")'s subsidiary, Sunshine Guojian Pharmac...

2020-12-14 22:28 1924

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc...

2020-11-23 21:28 10473

3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry

SHANGHAI, Sept. 2, 2020 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) ...

2020-09-02 02:15 10348
3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry

3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2020-03-31 12:29 9465
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research

SHANGHAI, March 1, 2020 /PRNewswire/ -- MPM Capital (MPM) and Dana-Farber Cancer Institute have joi...

2020-03-01 16:30 1563